Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

Jonathan M. Loree(University of British Columbia), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Seerat Anand(The University of Texas MD Anderson Cancer Center), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Anirudh Gothwal(Baylor University), Lee M. Ellis(The University of Texas MD Anderson Cancer Center), Gauri Varadhachary(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Joseph M. Unger(Fred Hutch Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center)
JAMA Oncology
August 16, 2019
10.1001/jamaoncol.2019.1870
Cited by 568

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|Annals of Oncology|2017|591
Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition
|Cancer Research|2009|578